Lyell Immunopharma grants options to director

Lyell Immunopharma director William JL Rieflin received a new stock option grant for 9,250 shares of common stock.

Rhea-AI Filing Summary

Lyell Immunopharma director William JL Rieflin received a new stock option grant for 9,250 shares of common stock. The option has an exercise price of $13.22 per share and expires on June 9, 2036.

According to the award terms, these option shares vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that meeting if his board service ends at that time) or the first anniversary of June 10, 2026, provided he continues serving through the vesting date. After this grant, his reported option holdings from this award total 9,250 shares.

Insider Trade Summary

Grant/Award: 9,250 shares

Grant/Award 1 txn

Insider RIEFLIN WILLIAM JL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	9,250	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 9,250 contracts (Direct)

Footnotes (1)

1. F1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Key Figures

Option shares granted: 9,250 shares Exercise price: $13.22 per share Underlying security: 9,250 shares common stock +3 more

6 metrics

Option shares granted 9,250 shares Director stock option award

Exercise price $13.22 per share Stock option strike price

Underlying security 9,250 shares common stock Shares subject to option

Expiration date June 9, 2036 Option term end

Grant/vesting reference date June 10, 2026 Used to determine vesting timing

Post-grant option holdings from award 9,250 options Total shares following transaction

Key Terms

Option (right to buy), exercise price, underlying security, Grant, award, or other acquisition, +1 more

5 terms

Option (right to buy) financial

"security_title: Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 13.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

underlying security financial

"underlying_security_title: Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of the stockholders financial

"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lyell Immunopharma (LYEL) report for William JL Rieflin?

Lyell Immunopharma reported that director William JL Rieflin received a grant of options for 9,250 shares of common stock. The options were awarded at a $13.22 exercise price and represent compensation, not an open‑market stock purchase or sale.

How many Lyell Immunopharma (LYEL) option shares were granted to the director?

The director was granted options covering 9,250 shares of Lyell Immunopharma common stock. These options give him the right to buy those shares in the future at a fixed $13.22 exercise price, subject to the vesting schedule and his continued board service.

What is the exercise price of the new Lyell Immunopharma (LYEL) stock options?

The granted options have an exercise price of $13.22 per share. This means the director can purchase Lyell Immunopharma common stock at $13.22 once the options vest, regardless of the market price at that future time, as long as the options remain outstanding.

When do William JL Rieflin’s Lyell Immunopharma (LYEL) options vest?

The options vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026. Vesting is conditioned on the director providing continuous service through the applicable vesting date described in the grant terms.

When do the newly granted Lyell Immunopharma (LYEL) options expire?

The granted options are scheduled to expire on June 9, 2036. After this expiration date, any unexercised portion of the 9,250-share award will lapse, and the director will no longer have the right to buy those shares at the $13.22 exercise price.

Is the Lyell Immunopharma (LYEL) Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant of options, not a market purchase or sale of shares. The transaction is coded as a grant or award acquisition, reflecting compensation that gives the director the future right to buy Lyell Immunopharma stock if the options vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RIEFLIN WILLIAM JL

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$13.22	06/10/2026		A		9,250		(1)	06/09/2036	Common Stock	9,250	$0	9,250	D

Explanation of Responses:

1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

	/s/ Mark Meltz, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)